Gonadorelin vs Triptorelin
Research Verdict
Triptorelin is the stronger research reference for the stated comparison criteria. Both FDA approved.
Quick Answers
Which is better, Gonadorelin or Triptorelin?
Triptorelin is the stronger research reference for the stated comparison criteria. Both FDA approved.
What is the key difference between Gonadorelin and Triptorelin?
Triptorelin is a long-acting depot GnRH agonist causing sustained HPG suppression; gonadorelin is short-acting preserving physiological pulsatility - the depot formulation makes triptorelin convenient for chronic suppression, while gonadorelin maintains axis function.
Evidence Comparison
Both FDA approved. Triptorelin (Trelstar): FDA approved for advanced prostate cancer, Phase 3 data, long-acting depot formulations (1, 3, and 6 month). Gonadorelin: FDA approved diagnostic. Triptorelin has more extensive Phase 3 oncology data.
Evidence Context Favoring Gonadorelin
Diagnostic HPG testing or pulsatile GnRH replacement where axis preservation is the goal.
Evidence Context Favoring Triptorelin
Prostate cancer or conditions requiring long-term HPG suppression - triptorelin depot formulations offer monthly to biannual dosing.
Side-by-Side Snapshot
| Evidence grade | Gonadorelin: Level A Triptorelin: Level A |
|---|---|
| Research status | Gonadorelin: Historical FDA Approval Triptorelin: FDA Approved |
| Primary category | Gonadorelin: Sexual Health Triptorelin: Sexual Health |
| Cited studies | Gonadorelin: 2 Triptorelin: 3 |